(firstQuint)Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study.

 Twelve patients with stage 3 to 4 kidney disease will receive an intervention for four weeks and a matching placebo in a crossover study design.

 Reduction of serum TMAO from baseline to end of intervention will be the primary endpoint.

.

 Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study@highlight

The project will investigate the modulation of flavin-containing monooxygenase (FMO) formation of the CVD risk factor trimethylamine-N-oxide (TMAO) in patients with kidney disease.

